Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
VERTEX PHARMACEUTICALS INC / MA (VRTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VRTX at 75.4/100 on a 32-signal composite quality model, placing it at rank #98 of 2,961 stocks — the top 5% of the AI-ranked universe. VRTX scores in the top quartile across balance sheet strength (94.6), profitability (94.3), revenue scale (88.5). Shareholder dilution risk is elevated at 22.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), VERTEX PHARMACEUTICALS INC / MA reports quarterly revenue of $3.3B, net income of $1.1B, an operating margin of 37.4%. Top institutional holders of VRTX by reported 13-F value include Capital World Investors, BlackRock, Capital Research Global Investors, based on the most recent SEC filings. VRTX trades on the Nasdaq exchange and files with the SEC under CIK 875320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VERTEX PHARMACEUTICALS INC / MA directly from SEC EDGAR.
AI Quality Score
75.4/100
AI Rank
#98
Revenue
$3.3B
Net Income
$1.1B
Free Cash Flow
$1.0B
Operating Margin
37.4%
VRTX key financials by period
VERTEX PHARMACEUTICALS INC / MA reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$12.0B
$4.0B
34.8%
FY 2024
10-K
$11.0B
$-535.6M
-2.1%
FY 2023
10-K
$9.9B
$3.6B
38.8%
FY 2022
10-K
$8.9B
$3.3B
48.2%
FY 2021
10-K
$7.6B
$2.3B
36.7%
FY 2020
10-K
$6.2B
$2.7B
46.0%
Institutions holding VRTX
Institutional investors reporting a position in VERTEX PHARMACEUTICALS INC / MA on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-04 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Total revenues rose 12% to $3.3B as ALYFTREK scaled to $573.6M, offsetting a 2% TRIKAFTA/KAFTRIO decline, while Vertex agreed to acquire Crinetics for ~$10.0 billion.
Biggest Revenue Drivers
TRIKAFTA/KAFTRIO$2,497.2M-2% YoY
CF franchise revenue shifting as patients initiate ALYFTREK
ALYFTREK$573.6M+266% YoY
Reimbursement secured in four additional countries, bringing total reimbursed countries to 25
Biggest Revenue Drivers
Total revenue: $3.3B+12% YoY
TRIKAFTA/KAFTRIO$2,497.2M-2% YoY
CF franchise revenue shifting as patients initiate ALYFTREK
ALYFTREK$573.6M+266% YoY
Reimbursement secured in four additional countries, bringing total reimbursed countries to 25
Other CF product revenues (KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI)$137.1M-29% YoY
CASGEVY$76.4M+151% YoY
FDA approval in children two years and older; German reimbursement secured for patients 12 and older
JOURNAVX$49.6M+313% YoY
Approximately 535,000 prescriptions filled in the quarter across hospital and retail settings
Largest Expense Items
Research and development expenses$993.8M+2% YoY
Investment in povetacicept, T1D, peripheral neuropathic pain and AMKD programs; offset by 2025 program discontinuations
Selling, general and administrative expenses$582.2M+37% YoY
Increased internal headcount and commercial investment to support JOURNAVX and the anticipated povetacicept launch in IgAN
Cost of sales$489.2M+20% YoY
Third-party CF royalties plus inventory costs; product mix shift raised the rate
Acquired in-process research and development expenses$21.4Mvs $2.2M a year ago
Upfront and milestone payments under collaboration and in-licensing arrangements
Margins: Cost of sales rose to 14.7% of net product revenues from 13.8%, driven by changes in product mix, partially offset by a lower blended royalty rate for CF medicines.
Watch Items from the Filing
Royalty Pharma arbitration alleges ALYFTREK royalty burden is approximately 8% versus Vertex's 4% position; ALYFTREK net revenues total $1.8B since inception.
Pending $10.0B Crinetics acquisition funded partly by a new $4.5B term loan; Vertex expects future net interest income (currently $120.6M quarterly) to decrease.
CF products remain $3,207.9M of $3,333.9M total revenues; TRIKAFTA/KAFTRIO fell 2% and other CF products fell 29% year over year.
SG&A up 37% to $582.2M ahead of the povetacicept IgAN launch, with a PDUFA target action date of November 30, 2026.
Ex-U.S. revenues of $1,277.5M grew 14%, aided by foreign exchange; $4.6B notional of currency forwards hedge forecasted revenues.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
